Table 4 |
||||
|
Summary of adverse events by type and study period. |
||||
| SOC Preferred Term |
Adverse Events 4-Weeks (n) |
(%)a |
Adverse Events Follow up (n) |
(%)b |
|
|
||||
| Patients |
64 |
60 |
||
| Patients who Experienced Adverse Events |
32 |
50.0 |
16 |
26.6 |
| Palpitations |
4 |
6.3 |
0 |
0 |
| Abdominal Pain Upper |
3 |
4.7 |
3 |
4.9 |
| Diarrhea |
4 |
6.3 |
2 |
3.3 |
| Dyspepsia |
7 |
10.9 |
0 |
0 |
| Gastrointestinal Pain |
10 |
15.6 |
3 |
4.9 |
| Nausea |
13 |
20.3 |
8 |
13.1 |
| Vomiting |
7 |
10.9 |
2 |
3.3 |
| Asthenia |
2 |
3.1 |
2 |
3.3 |
| Fatigue |
8 |
12.5 |
9 |
14.8 |
| Pain |
4 |
6.3 |
0 |
0 |
| Headache |
8 |
12.5 |
6 |
9.8 |
| Tremor |
4 |
6.3 |
1 |
1.6 |
| Insomnia |
4 |
6.3 |
2 |
3.3 |
| Irritability |
1 |
1.6 |
3 |
4.9 |
| Hyperhidrosis |
8 |
12.5 |
3 |
4.9 |
| Rash |
2 |
3.1 |
2 |
3.3 |
|
|
||||
|
a: Percentage based on all 64 patients. b: Percentage based on the 60 patients who were treated with Suboxone during the follow-up period. |
||||
|
Simojoki et al. Substance Abuse Treatment, Prevention, and Policy 2008 3:16 doi:10.1186/1747-597X-3-16 |
||||
